Abstract: The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-? tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation efficiency of drug in liposome as well as to enhance the stability of drug in liposomes. Such liposome is capable to increase the skin permeation of drugs. The preparation method comprises the following steps: (1) adding the drug to a Vitamin E derivative solution to form a mixture; and (2) adding at least one phosphatidyl choline to the mixture, after hydration from either sonication or homogenization.
Type:
Application
Filed:
March 17, 2008
Publication date:
November 27, 2008
Applicant:
Industrial Technology Research Institute
Abstract: Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.).
Type:
Application
Filed:
February 6, 2006
Publication date:
November 20, 2008
Applicant:
OREGON HEALTH & SCIENCE UNIVERSITY
Inventors:
Jean-Baptiste Roullet, John C. Crabbe, JR., Pamela Metten
Abstract: The present invention relates to compositions for the treatment of pilosebaceous gland inflammations, especially of the hair follicle and its appendages, in particular of Acne Vulgaris and Folliculitis, comprising as active ingredient AIF or chemical compounds which finally release AIF, or combinations of aluminum and fluoride salts which finally release AIF. AIF in accordance with the present invention relates to Aluminum fluoride (Aluminum Trifluoride; Aluminum Fluoride), CAS No 7784-18-1, EINECS No. 232-051-1, having an empirical formula of AIF3. Said compositions have, inter alia, pharmaceutical, cosmetic or quasi-cosmetic properties. The present invention also relates to the use of said compositions in said treatment, and to methods for the treatment of pilosebaceous gland inflammations with said compositions.
Abstract: A method is provided for treating a degenerative disease in a vertebrate eye. A method is further provided for preventing photoreceptor degeneration in a vertebrate eye.
Type:
Application
Filed:
February 24, 2006
Publication date:
November 6, 2008
Applicant:
University of Washington
Inventors:
Krzysztof Palczewski, Marcin Golczak, Vladimir Kuksa
Abstract: A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.
Abstract: The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.
Abstract: The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided.
Type:
Application
Filed:
April 16, 2007
Publication date:
October 16, 2008
Applicant:
Wyeth
Inventors:
Yong Dai, Alan M. Goldberg, Michael A. Goode, Raymond Alan Bartolucci, James O. Frazier
Abstract: A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described.
Abstract: An oral composition for the prevention, reduction or treatment of radiation injury including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivatives, selenium, selenium compounds, anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure.
Abstract: Improved composition for the administration of a physiologically active agent through the skin which comprises at least one vegetable oil, oleic acid, and at least one lactone of a saturated or unsaturated fatty acid of 5 to 22 carbon atoms, said two last components acting as absorption enhancers. Using said composition, unexpected increased values of the absorption of the physiologic active agent through the skin are obtained due to an unpredictable synergistic effect.
Type:
Application
Filed:
November 3, 2006
Publication date:
October 9, 2008
Applicant:
LABORATORIOS BELMAC, S.A.
Inventors:
Luis Carvajal Martin, Francisco Sevilla Tirado, Yolanda Aznar Antonanzas
Abstract: The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent.
Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
Type:
Grant
Filed:
November 4, 2005
Date of Patent:
October 7, 2008
Assignee:
Sirion Therapeutics, Inc.
Inventors:
Nathan L. Mata, Kenneth Widder, Jay Lichter
Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to a bout 50% of a combination of retinoid boosters.
Type:
Application
Filed:
March 10, 2008
Publication date:
September 25, 2008
Applicant:
CONOPCO, INC., D/B/A UNILEVER
Inventors:
Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
Abstract: The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular useful for treating wrinkles but also for thickening the epidermis and for improving hair growth.
Type:
Application
Filed:
March 23, 2005
Publication date:
September 18, 2008
Inventors:
Volker Schehlmann, Jochen Klock, Philippe Emmanuel Maillan, Juerger H. Vollhardt, Anthony Rawlings, Raphael Beumer
Abstract: The invention concerns a pharmaceutical or cosmetic composition, characterized in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence of an allergenic agent.
Type:
Application
Filed:
March 3, 2008
Publication date:
September 11, 2008
Inventors:
Philippe Msika, Nathalie Piccardi, Antoine Piccirilli
Abstract: There is disclosed method of killing nematodes comprising the step of applying an effective amount of a nematicidal composition comprising a terpene component and compositions suitable for use in the method. The terpene component is preferably in association with water, either as a solution or a suspension. An excipient may also be included, which is suitably hollow glucan particles which encapsulate the terpene component.
Type:
Application
Filed:
January 24, 2005
Publication date:
September 11, 2008
Inventors:
Lanny Franklin, Elizabeth Cloud, Lanna Knapp, Gary Ostroff
Abstract: This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.
Type:
Application
Filed:
October 31, 2007
Publication date:
September 4, 2008
Applicant:
Oregon Health and Sciences University
Inventors:
Jean-Baptiste Roullet, David A. McCarron
Abstract: The invention provides a nutrient composition for augmenting immune strength or physiological detoxification. The nutrient composition consists of an optimal combination of an effective amount of at least one vitamin antioxidant, at least one mineral antioxidant and a highly saturable amount of at least three high potency antioxidants. The at least one vitamin antioxidant can be vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or beta-carotene and the at least one mineral antioxidant can be zinc or selenium. The at least three high potency antioxidants can be alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione. Also provided is a nutrient composition for augmenting immune strength or physiological detoxification that consists of an optimal combination of an effective amount of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants.
Abstract: This invention relates to a treatment pad which may be used in cosmetic treatment and which produces soothing, relaxing, calming and similar effects in persons. The treatment pad comprises 0.1 to 90% weight (% wt) of a hydrophilic polymer selected from the group consisting of polyvinyl alcohol (PVA), polyethylene glycol (EG), polyacrylamide (PAAm), polyacrylic acid (PAAc), polyhydroxyethyl methacrylate (PHEMA) and polyethylene oxide (PEO); 0.01 to 0.
Abstract: An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.
Abstract: A medicament for preventive and/or therapeutic treatment of a lower urinary tract symptom caused by a lower urinary tract disorder, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid
Abstract: The present invention features a composition including (i) a retinoid, and (ii) an interleukin-8 inhibitor. The composition provides reduced irritation to human skin.
Abstract: The invention provides a multivitamin and mineral nutritional supplement composition comprising at least one polyvalent metal and at least one oxidizable vitamin with substantially improved resistance to reactions that lead to darkening and/or spotting and reactions that may reduce the potency of oxidizable vitamins. The composition is a multivitamin and mineral composition comprising at least one polyvalent metal and at least one oxidizable vitamin wherein the composition is substantially free of mobile bound water. The invention also includes methods for making such a composition and methods of preventing or reducing oxidation, improving the stability of oxidizable vitamins, and stabilizing the disintegration time of a multi-vitamin and mineral nutritional supplement composition.
Type:
Application
Filed:
February 15, 2007
Publication date:
August 21, 2008
Applicant:
Wyeth
Inventors:
Alan M. Goldberg, Steven Dills, William Mark, Bruce Sutton, Chad Byerley
Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
Type:
Application
Filed:
March 24, 2008
Publication date:
July 24, 2008
Applicant:
GALDERMA RESEARCH & DEVELOPMENT, S.N.C.
Abstract: The present invention relates to an anti-aging cosmetic composition, and more particularly, the present invention relates to an anti-aging cosmetic composition containing Hibiscus esculentus extracts and at least one selected from the group consisting of oleanolic acid, ursolic acid, glycyrhetinic acid and retinol, showing high safety to skin and wrinkle-improvement effect.
Type:
Application
Filed:
November 8, 2005
Publication date:
July 3, 2008
Inventors:
Chan Koo Kang, Young Jin Lee, Sang Hoon Han, Seung Hun Kim
Abstract: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.
Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.
Abstract: A composition for topical application comprises a dispersed phase comprising an active agent and a polymer or lipid; and a gelled continuous phase comprising a viscosity modifier and a solvent. The composition can provide an active agent to skin or mucous membranes in a controlled release form.
Abstract: Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.
Type:
Application
Filed:
August 28, 2007
Publication date:
May 29, 2008
Inventors:
Donald Massaro, Gloria DeCarlo Massaro, Roshantha A. Chandraratna
Abstract: The subject invention provides a composition comprising a mixture of polypeptides in the form of a tannate salt wherein each polypeptide is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine and L-Lysine, methods of preparation and uses thereof.
Abstract: The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with an antifungal agent. In a preferred form, the preparation further comprises, a fatty acid source such as a fish oil. In a preferred embodiment, cod liver oil and tolnaftate are used in combination with triacetin. The concentrations of these constituents are 96.0-99.0% concentration triacetin, 0.5-3.0% concentration tolnaftate and 0.5-1.0% concentration cod liver oil, in one preferred embodiment. Other compounds, such as ethyl alcohol, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agent tolnaftate.
Abstract: Various medical conditions previously treated by injection or surgery are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, varodilators and botulinum toxin. Conditions as diverse as spider veins, erectile dysfunction and facial wrinkles can be effectively treated with the compositions.
Abstract: Compositions that benefit skin and that reduce irritation of the skin are described. The compositions have a skin benefit agent like a hydroxy acid and a vanilloid receptor antagonist. The compositions of this invention can reduce wrinkles on the skin when applied, and they can be formulated to contain glycolic acid and capsazepine.
Abstract: An anti-atherosclerosis composition comprising a LDL-oxidation inhibiting effective amount of phytoene, phytofluene or mixtures thereof and a method for inhibiting the progression of atherosclerosis.
Abstract: The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, and methods of treatment with layered tablets and fractional tablets derived from breaking said tablets.
Abstract: Orlistat is an oral lipase inhibitor that blocks the absorption of ingested fats from the small intestines, to enable proven weight loss. Fat-soluble vitamin deficiencies can be a consequence of orlistat use, especially if used for a long time without medical supervision. The present invention comprises a fat-soluble-only vitamin complex, specifically for use with orlistat, which vitamin complex contains a significantly increased amount of vitamin D, to prevent osteoporosis and to reduce fracture risk.
Abstract: This invention relates to topical creams which retard sun exposure damage to skin and restore skin health. More particularly, this invention pertains to a novel topical skin cream formulation which retards sun damage to skin and restores skin health comprising: (a) vitamin A retinyl at a concentration of 0.2% to 10% weight, and/or retinol at a concentration of 0.2% to 10% weight; (b) vitamin C at a concentration of 5 % to 30% weight; (c) vitamin E at a concentration of 1% to 10% weight; (d) zinc sulfate at a concentration of 2% to 5% weight; and (e) the remainder, water and skin compatible thickeners, emulsifiers, emollients and moisturizers, having a pH of about 3 to 6.
Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.
Abstract: The invention relates to a stable pharmaceutical formulation comprising an intimate admixture or admixture of crystalline or amorphous atorvastatin calcium, and a stabilizing-effective amount of a water-insoluble alkaline excipient or a combination of one or more water-insoluble alkaline excipients thereof, a stabilizing-effective amount of an antioxidant or a combination of one or more antioxidants thereof, and at least one or more additional pharmaceutically acceptable inert excipients or carriers, and a method for the preparation of the said formulation by wet and dry granulation. The invention further relates to a stabilized intimate admixture of atorvastatin calcium, a water-insoluble alkaline excipient and an antioxidant and a method for the preparation of the said intimate admixture by co-precipitation and co-milling.
Abstract: A smoking cessation device is provided. The smoking cessation device includes a dispensing member comprising porous plastic defining a matrix of an internal network of passages in communication with pores on the exterior of the device. The device is preferably sized and structured like a cigarette or other combustible smoking device. Residing within the matrix is a dispensate extractable therefrom upon exposure to a fluid. In one form the dispensate may be a tobacco derivative including one or more of nicotine, tobacco flavoring, menthol, vitamins, minerals, therapeutic agents, and/or additional flavoring.
Abstract: The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel.
Abstract: A dermatological composition which may be used for the topical treatment of the skin, hair, or nails of mammals, comprising tamanu oil, an unsaturated fatty acid, and arnica oil, optionally including Vitamins E and A. The dermatological composition may be combined with other components to form a shampoo, conditioner, lotion, cream, spray, salve, or other cosmetic product in liquid, paste, or powder form.
Abstract: Disclosed is a therapeutic nutritional compound for treating and supporting the immune response in a mammal, particularly a human baby or child, and the treatment method. Additionally, the therapeutic nutritional compound can be used in conjunction with a vaccine or immunization regimen to reduce the potential undesirable effects caused by other components of the vaccine. The therapeutic nutritional compound can include glutathione, selenium, zinc and antioxidants.
Abstract: An emulsion comprising: water; hydrophilic particles; and hydrophobic particles; wherein the hydrophilic and hydrophobic particles form shells encapsulating a gas that are suspended in the water, said shells comprising an external layer of hydrophilic particles and an internal layer of hydrophobic particles adjacent to the layer of hydrophilic particles.
Abstract: The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.
Type:
Grant
Filed:
November 18, 2002
Date of Patent:
October 9, 2007
Assignee:
BASF Aktiengesellschaft
Inventors:
Wolfgang Hähnlein, Morten Mohr Hansen, Jes Elenius Olesen, Anne Grethe Tobiasen
Abstract: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent.
Type:
Application
Filed:
March 20, 2007
Publication date:
September 27, 2007
Applicant:
L'OREAL
Inventors:
Sheldon R. Pinnell, Jan Zielinski, Isabelle Hansenne
Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 and an amino acid solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 and the amino acid, such as carnitine, i.e., carnitine tartrate, in formulations, such as soft gel capsules.
Abstract: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision. The dietary supplements of the invention contain cobeadlets comprising vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthing. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, other vitamins and minerals.